Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr Sp Biotech ETF | 12.41% | Add +127.5% | 613,000 | $74.27 | $46M | +343,500 | +$21M |
| STXS - Stereotaxis | 6.86% | Hold | 13,680,554 | $1.84 | $25M | — | — |
| BHVN - Biohaven | 4.37% | Add +41.9% | 110,100 | $145.71 | $16M | +32,500 | +$7M |
| Adicet Bio | 3.72% | Add +30.7% | 935,766 | $14.60 | $14M | +219,894 | −$634K |
| FATE - Fate Therapeutics | 3.72% | Add +10.0% | 550,940 | $24.78 | $14M | +50,010 | −$6M |
| XENE - Xenon Pharmaceuticals | 3.64% | Add +15.4% | 438,623 | $30.42 | $13M | +58,460 | +$2M |
| Blueprint Medicines | 3.60% | Add +6.1% | 261,280 | $50.51 | $13M | +15,000 | −$3M |
| ASND - Ascendis Pharma A/S | 3.53% | Add +354.8% | 139,212 | $92.96 | $13M | +108,600 | +$9M |
| NDAQ - Nasdaq Omx | 3.29% | Hold | 102,500 | $117.63 | $12M | — | — |
| CYTK - Cytokinetics | 2.26% | Hold | 211,495 | $39.29 | $8M | — | — |
| NBIX - Neurocrine Biosciences | 2.20% | Reduce −1.2% | 82,655 | $97.48 | $8M | −1,000 | +$214K |
| Karuna Therapeutics | 2.14% | Reduce −24.4% | 62,053 | $126.50 | $8M | −20,000 | −$3M |
| IDYA - Ideaya Biosciences | 2.06% | Add +11.9% | 548,561 | $13.80 | $8M | +58,500 | +$2M |
| NRIX - Nurix Therapeutics | 1.96% | Add +4.3% | 566,695 | $12.67 | $7M | +23,351 | −$432K |
| SNDX - Syndax Pharmaceuticals | 1.95% | Reduce −0.3% | 370,987 | $19.24 | $7M | −1,000 | +$673K |
| Merus | 1.62% | Add +11.9% | 262,891 | $22.64 | $6M | +27,902 | −$261K |
| RVMD - Revolution Medicines | 1.59% | Add +29.2% | 299,785 | $19.49 | $6M | +67,684 | −$78K |
| Sage Therapeutics | 1.59% | Hold | 180,306 | $32.30 | $6M | — | — |
| ALEC - Alector | 1.53% | Add +88.7% | 552,438 | $10.16 | $6M | +259,691 | +$1M |
| EWTX - Edgewise Therapeutics | 1.51% | Add +95.1% | 695,959 | $7.96 | $6M | +339,209 | +$2M |
| DXCM - Dexcom | 1.47% | Add +300.0% | 72,552 | $74.53 | $5M | +54,414 | −$4M |
| Mirati Therapeutics | 1.46% | Add +86.4% | 79,600 | $67.14 | $5M | +36,900 | +$2M |
| Cymabay Therapeutics | 1.44% | Add +5.6% | 1,787,569 | $2.95 | $5M | +95,000 | +$9K |
| RCUS - Arcus Biosciences | 1.30% | Add +29.3% | 187,717 | $25.34 | $5M | +42,500 | +$174K |
| Natus Medical | 1.28% | Reduce −24.7% | 143,600 | $32.77 | $5M | −47,035 | −$304K |
| APLSUSD - Apellis Pharmaceuticals | 1.19% | Add +3.2% | 96,935 | $45.22 | $4M | +3,000 | −$390K |
| Morphic | 1.16% | Add +7.7% | 195,467 | $21.70 | $4M | +14,000 | −$3M |
| Cardiovascular Sys | 1.12% | Hold | 286,988 | $14.36 | $4M | — | — |
| IPSC - Century Therapeutics | 1.09% | Add +85.0% | 475,367 | $8.40 | $4M | +218,475 | +$759K |
| Iveric Bio | 1.06% | Add +34.8% | 402,476 | $9.62 | $4M | +104,000 | −$1M |
| Holding | 0.99% | Reduce −18.5% | 48,452 | $75.25 | $4M | −11,000 | +$2M |
| F-Star Therapeutics | 0.98% | Reduce −16.9% | 576,881 | $6.26 | $4M | −116,904 | +$1M |
| Otonomy | 0.83% | Reduce −1.8% | 1,470,199 | $2.08 | $3M | −27,315 | −$536K |
| ATRC - Atricure | 0.80% | Hold | 72,029 | $40.86 | $3M | — | — |
| Kinnate Biopharma | 0.77% | Add +51.5% | 224,451 | $12.61 | $3M | +76,300 | +$1M |
| AXGN - Axogen | 0.74% | Hold | 332,103 | $8.19 | $3M | — | — |
| Kalvista Pharmaceuticals | 0.71% | Add +39.3% | 265,663 | $9.84 | $3M | +75,000 | −$196K |
| 89BIO | 0.67% | Add +136.6% | 766,774 | $3.22 | $2M | +442,721 | +$1M |
| Dice Therapeutics | 0.66% | Add +66.9% | 156,904 | $15.52 | $2M | +62,904 | +$637K |
| LKFT - Galapagos | 0.65% | Hold | 42,675 | $55.79 | $2M | — | — |
| BCYC - Bicycle Therapeutics | 0.60% | Add +146.6% | 131,200 | $16.78 | $2M | +78,000 | −$132K |
| Iteos Therapeutics | 0.59% | Add +17.9% | 105,298 | $20.60 | $2M | +16,000 | −$705K |
| Aerie Pharmaceuticals | 0.59% | Hold | 289,040 | $7.50 | $2M | — | — |
| KURA - Kura Oncology | 0.59% | Add +4.0% | 117,829 | $18.33 | $2M | +4,500 | +$338K |
| Affimed | 0.52% | Add +20.1% | 686,282 | $2.77 | $2M | +115,000 | −$596K |
| Mersana Therapeutics | 0.51% | Add +15.3% | 406,763 | $4.62 | $2M | +54,000 | +$471K |
| ORIC - Oric Pharmaceuticals | 0.51% | New | 415,926 | $4.48 | $2M | +415,926 | +$2M |
| ARAY - Accuray | 0.50% | Hold | 941,800 | $1.96 | $2M | — | — |
| Surface Oncology | 0.49% | Add +61.8% | 1,100,000 | $1.64 | $2M | +420,000 | −$195K |
| BMEA - Biomea Fusion | 0.45% | Reduce −64.3% | 136,935 | $11.98 | $2M | −246,988 | −$72K |
| TCOM - Field Trip Health | 0.44% | Reduce −13.1% | 1,904,141 | $0.8403 | $2M | −287,167 | −$1M |
| AUTL - Autolus Therapeutics | 0.38% | Hold | 496,150 | $2.83 | $1M | — | — |
| Pardes Biosciences | 0.38% | Add +7.1% | 451,105 | $3.07 | $1M | +29,948 | −$2M |
| Ngm Biopharmaceuticals | 0.38% | Hold | 107,653 | $12.82 | $1M | — | — |
| VKTX - Viking Therapeutics | 0.36% | Add +3.4% | 462,400 | $2.89 | $1M | +15,000 | −$6K |
| Mereo Biopharma Group | 0.33% | Reduce −9.9% | 1,096,513 | $1.12 | $1M | −120,100 | −$135K |
| WVE - Wave Life Sciences | 0.33% | Reduce −4.6% | 372,361 | $3.25 | $1M | −17,800 | +$430K |
| Regulus Therapeutics | 0.31% | New | 555,555 | $2.07 | $1M | +555,555 | +$1M |
| Keros Therapeutics | 0.29% | New | 39,000 | $27.64 | $1M | +39,000 | +$1M |
| Mei Pharma | 0.29% | Hold | 1,767,146 | $0.6049 | $1M | — | — |
| Neuronetics | 0.27% | Hold | 313,717 | $3.21 | $1M | — | — |
| BWAY - Brainsway | 0.26% | Hold | 200,000 | $4.83 | $966K | — | — |
| Radius Health | 0.26% | Reduce −52.1% | 91,935 | $10.37 | $953K | −100,043 | −$742K |
| Nextcure | 0.24% | Hold | 187,696 | $4.70 | $882K | — | — |
| SCYXEUR - Scynexis | 0.23% | Add +274.9% | 454,492 | $1.86 | $845K | +333,250 | +$371K |
| CMPS - Compass Pathways | 0.22% | Hold | 74,890 | $10.82 | $810K | — | — |
| BDTX — | 0.21% | Hold | 313,600 | $2.46 | $771K | — | — |
| Genfit S A | 0.16% | Hold | 187,940 | $3.22 | $605K | — | — |
| Adaptimmune Therapeutics | 0.16% | Hold | 351,064 | $1.70 | $597K | — | — |
| Macrogenics | 0.15% | Hold | 192,000 | $2.95 | $566K | — | — |
| Gh Research | 0.15% | Hold | 55,000 | $9.98 | $549K | — | — |
| CMPX - Compass Therapeutics | 0.14% | Add +1.0% | 198,094 | $2.65 | $525K | +2,003 | +$256K |
| Theseus Pharmaceuticals | 0.12% | Add +2.2% | 81,899 | $5.53 | $453K | +1,775 | −$471K |
| Venus Concept | 0.12% | Hold | 968,187 | $0.4638 | $449K | — | — |
| Rigel Pharmaceuticals | 0.12% | Reduce −56.5% | 390,066 | $1.13 | $441K | −506,034 | −$2M |
| Sutro Biopharma | 0.12% | Hold | 84,700 | $5.21 | $441K | — | — |
| Masimo | 0.11% | Hold | 3,000 | $130.67 | $392K | — | — |
| Compugen | 0.10% | Add +57.6% | 205,202 | $1.85 | $380K | +75,000 | −$39K |
| Lava Therapeutics | 0.10% | Reduce −7.9% | 128,335 | $2.95 | $379K | −10,997 | −$234K |
| INGN - Inogen | 0.10% | Hold | 15,000 | $24.20 | $363K | — | — |
| Vigil Neuroscience | 0.07% | Hold | 99,754 | $2.58 | $257K | — | — |
| Phasebio Pharmaceuticals | 0.06% | Hold | 378,611 | $0.5996 | $227K | — | — |
| MDGL - Madrigal Pharmaceuticals | 0.06% | Hold | 3,100 | $71.61 | $222K | — | — |
| Holding | 0.06% | Hold | 140,000 | $1.58 | $221K | — | — |
| Connect Biopharma | 0.06% | New | 250,000 | $0.8720 | $218K | +250,000 | +$218K |
| Aslan Pharmaceuticals | 0.05% | Add +41.0% | 343,720 | $0.4946 | $170K | +100,000 | −$49K |
| ANNX - Annexon | 0.04% | Add +32.5% | 40,796 | $3.77 | $154K | +10,000 | +$70K |
| LRMR - Larimar Therapeutics | 0.03% | Hold | 49,996 | $1.96 | $98K | — | — |
Showing top 50 of 88 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Athira Pharma | 0.57% | Exit | 0 | $13.50 | $2M | −160,983 | −$2M |
| COGT - Cogent Biosciences | 0.44% | Exit | 0 | $7.49 | $2M | −223,554 | −$2M |
| Regulus Therapeutics | 0.43% | Exit | 0 | $0.2981 | $2M | −5,555,555 | −$2M |
| Immunocore | 0.42% | Exit | 0 | $29.90 | $2M | −53,878 | −$2M |
| PHVS - Pharvaris | 0.16% | Exit | 0 | $18.14 | $628K | −34,615 | −$628K |
| Harpoon Therapeutics | 0.14% | Exit | 0 | $4.97 | $523K | −105,163 | −$523K |
| Surgalign | 0.05% | Exit | 0 | $0.3036 | $176K | −579,710 | −$176K |
| Infinity Pharmaceuticals | 0.04% | Exit | 0 | $1.14 | $137K | −120,097 | −$137K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2